Orion Pharma Secures European Rights to Pembrolizumab Biosimilar via Qilu Pharma Deal
Event summary
- Orion Pharma has signed an agreement with Qilu Pharma Europe to commercialize an intravenous pembrolizumab biosimilar in Europe.
- Orion gains exclusive distribution, marketing, and sales rights for the biosimilar in the region.
- Qilu will supply the product and receive profit-sharing, plus development, regulatory, and sales milestone payments.
- Pembrolizumab is an immune checkpoint inhibitor used to treat various cancers.
- Orion's net sales in 2025 were EUR 1,890 million.
The big picture
This deal aligns with Orion's strategic focus on expanding its oncology portfolio and increasing access to affordable cancer treatments. The biosimilars market is growing rapidly as patents on blockbuster biologics expire, creating opportunities for companies like Orion to capture market share. The success of this partnership will hinge on Orion's ability to navigate regulatory hurdles and establish a strong commercial presence in Europe.
What we're watching
- Regulatory Approval
- The pace at which Qilu secures regulatory approval for the pembrolizumab biosimilar will determine Orion's timeline for market entry.
- Market Penetration
- Whether Orion can effectively compete with existing pembrolizumab offerings in Europe, particularly given the dominance of branded therapies.
- Revenue Impact
- How the profit-sharing and milestone payments structure will affect Orion's financials in the near to medium term.
Related topics
